Drug name - Zemdri
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9688711 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(6 years from now) | |
| US8383596 | CIPLA USA | Antibacterial aminoglycoside analogs |
Jun, 2031
(8 years from now) | |
| CN101868472B | CIPLA USA | Antibacterial Amino Glycoside Analogue |
Nov, 2028
(6 years from now) | |
| CN103360440B | CIPLA USA | Antibacterial Aminoglycoside Analogues |
Nov, 2028
(6 years from now) | |
| CN103360440A | CIPLA USA | Antibacterial Amino Glycoside Analogue |
Nov, 2028
(6 years from now) | |
| CN101868472A | CIPLA USA | Antibacterial Aminoglycoside Analogues |
Nov, 2028
(6 years from now) | |
| IN201004165P1 | CIPLA USA | Antibacterial Aminoglycoside Analogs |
Nov, 2028
(6 years from now) | |
| IN282636B | CIPLA USA | Novel Aminoglycoside Compounds |
Nov, 2028
(6 years from now) | |
| EP3150617A1 | CIPLA USA | Antibacterial Aminoglycoside Analogs |
Nov, 2028
(6 years from now) | |
| EP2217610B1 | CIPLA USA | Antibacterial Aminoglycoside Analogs |
Nov, 2028
(6 years from now) | |
| EP3150617B1 | CIPLA USA | Antibacterial Aminoglycoside Analogs |
Nov, 2028
(6 years from now) | |
| EP2217610A1 | CIPLA USA | Antibacterial Aminoglycoside Analogs |
Nov, 2028
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9266919 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(6 years from now) | |
| US8822424 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(6 years from now) | |
Drugs and Companies using PLAZOMICIN SULFATE ingredient
Treatment: Method of using plazomicin to treat bacterial infections
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 500MG BASE/10ML (EQ 50MG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.